Borroto-Esoda K - Search Results

1

A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus.

Fischer WA 2nd, Eron JJ Jr, Holman W, Cohen MS, Fang L, Szewczyk LJ, Sheahan TP, Baric R, Mollan KR, Wolfe CR, Duke ER, Azizad MM, Borroto-Esoda K, Wohl DA, Coombs RW, James Loftis A, Alabanza P, Lipansky F, Painter WP. Fischer WA 2nd, et al. Among authors: borroto esoda k. Sci Transl Med. 2022 Jan 19;14(628):eabl7430. doi: 10.1126/scitranslmed.abl7430. Epub 2022 Jan 19. Sci Transl Med. 2022. PMID: 34941423 Free PMC article. Clinical Trial.

2

Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine.

Svarovskaia ES, Margot NA, Bae AS, Waters JM, Goodman D, Zhong L, Borroto-Esoda K, Miller MD. Svarovskaia ES, et al. J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):174-80. doi: 10.1097/QAI.0b013e31814258c0. J Acquir Immune Defic Syndr. 2007. PMID: 17667333 Clinical Trial.

3

Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy.

Goodman DD, Zhou Y, Margot NA, McColl DJ, Zhong L, Borroto-Esoda K, Miller MD, Svarovskaia ES. Goodman DD, et al. AIDS. 2011 Jan 28;25(3):325-33. doi: 10.1097/QAD.0b013e3283427dcb. AIDS. 2011. PMID: 21157296 Clinical Trial.

4

Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303).

Schwebke JR, Sobel R, Gersten JK, Sussman SA, Lederman SN, Jacobs MA, Chappell BT, Weinstein DL, Moffett AH, Azie NE, Angulo DA, Harriott IA, Borroto-Esoda K, Ghannoum MA, Nyirjesy P, Sobel JD. Schwebke JR, et al. Among authors: borroto esoda k. Clin Infect Dis. 2022 Jun 10;74(11):1979-1985. doi: 10.1093/cid/ciab750. Clin Infect Dis. 2022. PMID: 34467969 Free PMC article. Clinical Trial.

5

Hepatitis B virus containing the I233V mutation in the polymerase reverse-transcriptase domain remains sensitive to inhibition by adefovir.

Curtis M, Zhu Y, Borroto-Esoda K. Curtis M, et al. J Infect Dis. 2007 Nov 15;196(10):1483-6. doi: 10.1086/522521. Epub 2007 Oct 31. J Infect Dis. 2007. PMID: 18008227

6

Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306).

Sobel R, Nyirjesy P, Ghannoum MA, Delchev DA, Azie NE, Angulo D, Harriott IA, Borroto-Esoda K, Sobel JD. Sobel R, et al. Among authors: borroto esoda k. BJOG. 2022 Feb;129(3):412-420. doi: 10.1111/1471-0528.16972. Epub 2021 Nov 8. BJOG. 2022. PMID: 34676663 Free PMC article. Clinical Trial.

7

Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails.

Mewshaw JP, Myrick FT, Wakefield DA, Hooper BJ, Harris JL, McCreedy B, Borroto-Esoda K. Mewshaw JP, et al. J Acquir Immune Defic Syndr. 2002 Jan 1;29(1):11-20. doi: 10.1097/00042560-200201010-00002. J Acquir Immune Defic Syndr. 2002. PMID: 11782585

8

Effects of HIV Q151M-associated multi-drug resistance mutations on the activities of (-)-beta-D-1',3'-dioxolan guanine.

Feng JY, Myrick F, Selmi B, Deval J, Canard B, Borroto-Esoda K. Feng JY, et al. Antiviral Res. 2005 Jun;66(2-3):153-8. doi: 10.1016/j.antiviral.2005.03.001. Epub 2005 Apr 26. Antiviral Res. 2005. PMID: 15885814

9

Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine.

Feng JY, Myrick FT, Margot NA, Mulamba GB, Rimsky L, Borroto-Esoda K, Selmi B, Canard B. Feng JY, et al. Nucleosides Nucleotides Nucleic Acids. 2006;25(1):89-107. doi: 10.1080/15257770500379157. Nucleosides Nucleotides Nucleic Acids. 2006. PMID: 16440988

10

In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine.

Borroto-Esoda K, Vela JE, Myrick F, Ray AS, Miller MD. Borroto-Esoda K, et al. Antivir Ther. 2006;11(3):377-84. Antivir Ther. 2006. PMID: 16759055

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

70 results

Search Page